Warning: Undefined array key "network" in /hshare1/ZETTAI_path_WA_slash_usr_slash_proj_KARA/usr/proj/tcng/htdocs/tcng.php on line 565
Edge
ADAM9 → EIF4EBP1
Networks Including this Edge
| GSE10780_egf1520 - GSE10780 - SiGN-BN HC+Bootstrap | Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue |
| GSE10890_egf1520 - GSE10890 - SiGN-BN HC+Bootstrap | mRNA Breast Cancer Cell Line Profiles |
| GSE12093_egf1520 - GSE12093 - SiGN-BN HC+Bootstrap | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE12276_egf1520 - GSE12276 - SiGN-BN HC+Bootstrap | Expression data from primary breast tumors |
| GSE13067_egf1520 - GSE13067 - SiGN-BN HC+Bootstrap | Expression data from primary colorectal cancers |
| GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| GSE17705_egf1520 - GSE17705 - SiGN-BN HC+Bootstrap | Endocrine Sensitivity Index Validation Dataset |
| GSE20194_egf1520 - GSE20194 - SiGN-BN HC+Bootstrap | MAQC-II Project: human breast cancer (BR) data set |
| GSE20271_egf1520 - GSE20271 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients |
| GSE20685_egf1520 - GSE20685 - SiGN-BN HC+Bootstrap | Microarray-based molecular subtyping of breast cancer |
| GSE21122_egf1520 - GSE21122 - SiGN-BN HC+Bootstrap | Whole-transcript expression data for soft-tissue sarcoma tumors and control normal fat specimens |
| GSE22597_egf1520 - GSE22597 - SiGN-BN HC+Bootstrap | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE2294_egf1520 - GSE2294 - SiGN-BN HC+Bootstrap | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23177_egf1520 - GSE23177 - SiGN-BN HC+Bootstrap | Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. |
| GSE23988_egf1520 - GSE23988 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE25055_egf1520 - GSE25055 - SiGN-BN HC+Bootstrap | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_egf1520 - GSE25066 - SiGN-BN HC+Bootstrap | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE2603_egf1520 - GSE2603 - SiGN-BN HC+Bootstrap | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26639_egf1520 - GSE26639 - SiGN-BN HC+Bootstrap | Expression Data from 226 patients of the REMAGUS02 trial |
| GSE30784_egf1520 - GSE30784 - SiGN-BN HC+Bootstrap | Gene expression profiling of oral squamous cell carcinoma (OSCC) |
| GSE3726_egf1520 - GSE3726 - SiGN-BN HC+Bootstrap | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE5206_egf1520 - GSE5206 - SiGN-BN HC+Bootstrap | Large-scale deployment of embryonic gene programming in human and murine colon cancer: a new target for intervention. |
| GSE5851_egf1520 - GSE5851 - SiGN-BN HC+Bootstrap | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE9936_egf1520 - GSE9936 - SiGN-BN HC+Bootstrap | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
